BiologicsFinancialSports Medicine

An unmet need for knees: Biotech Histogenics sets terms for $60 million IPO

Keywords / Tickers: HSGX, XON
Related Links: Upcoming IPOs
Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button
Close